Essa Pharma is a clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment of cancer
With a commitment to advancing targeted treatments, the company primarily works on potent small molecule inhibitors designed to selectively target and inhibit the activity of specific proteins involved in cancer cell growth and survival. Essa Pharma aims to address significant unmet needs in oncology, particularly in the treatment of prostate cancer, by leveraging its expertise in medicinal chemistry and drug development to bring new options to patients. Through its research and development initiatives, the company strives to enhance patient outcomes and improve the quality of life for those affected by cancer.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ESSA Pharma To Contact Him Directly To Discuss Their Options
NEW YORK, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of ESSA Pharma Inc. (NASDAQEPIX), Innovative Industrial Properties, Inc. NYSE:IIPRNYSEIIPR)(NYSE: SQNYSESQ, and Crocs, Inc. (NASDAQ: CROXNASDAQ). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against ESSA Pharma Inc. (“ESSA” or “the Company”) (NASDAQEPIX) and certain of its officers.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ESSA Pharma To Contact Him Directly To Discuss Their Options
NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against ESSA Pharma Inc. (“ESSA” or the “Company”) (NASDAQEPIX) in the United States District Court for the Eastern District of Wisconsin on behalf of all persons and entities who purchased or otherwise acquired ESSA securities between December 12, 2023 and October 31, 2024, both dates inclusive (the “Class Period”). Investors have until March 25, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
SAN DIEGO, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired ESSA Pharma Inc. (NASDAQEPIX) securities between December 12, 2023 and October 31, 2024. ESSA is a clinical stage pharmaceutical company that focuses on the development of small molecule drugs for the treatment of prostate cancer. The Company's lead product candidate was masofaniten, which was in clinical trial in combination with enzalutamide compared with enzalutamide alone in patients with metastatic CRPC.
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ESSA Pharma Inc. (“ESSA” or “the Company”) (NASDAQEPIX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers and acquirers of securities of ESSA Pharma Inc. (NASDAQEPIX) between December 12, 2023 and October 31, 2024, inclusive (the “Class Period”). The lawsuit describes ESSA as a “clinical stage pharmaceutical company that focuses on the development of small molecular drugs for the treatment of prostate cancer.”
ESSA Pharma terminates its Phase 2 masofaniten trial in prostate cancer after interim data shows no added efficacy over enzalutamide alone, shifting focus to other priorities.
ESSA Pharma shares fell 22.6% at $6.80 yesterday. Explore masofaniten's promising Phase 1/2 results in prostate cancer treatment. Updated data, PSA reductions, and financial strength.
Shares of Humana Inc. (NYSEHUM) fell sharply during Thursday’s session after the company reported fourth-quarter FY23 earnings and issued 2024 guidance.
U.S. stock futures were lower this morning, with the Nasdaq futures falling around 100 points on Tuesday. Here are some big stocks recording gains in today’s pre-market trading session.
